Nina Shah, MD, of the University of California, San Francisco School of Medicine, discussed the latest updates in multiple myeloma therapies and regimens in the frontline and subsequent settings presented at the 2019 ASH Annual Meeting. “After this meeting, we’re going to have a better idea of how to use the drugs we already have and generate some hypotheses about combining things and how to repurpose them later in different lines of therapy,” she said.
